JP4463206B2 - グリチルリチン高濃度製剤 - Google Patents
グリチルリチン高濃度製剤 Download PDFInfo
- Publication number
- JP4463206B2 JP4463206B2 JP2005512629A JP2005512629A JP4463206B2 JP 4463206 B2 JP4463206 B2 JP 4463206B2 JP 2005512629 A JP2005512629 A JP 2005512629A JP 2005512629 A JP2005512629 A JP 2005512629A JP 4463206 B2 JP4463206 B2 JP 4463206B2
- Authority
- JP
- Japan
- Prior art keywords
- glycyrrhizin
- cysteine
- pharmaceutical composition
- aminoacetic acid
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Description
グリチルリチン酸モノアンモニウム16mg/mL(グリチルリチンとして)、システイン塩酸塩8mg/mL、アミノ酢酸160mg/mLの配合比になるように溶存酸素の少ない水に溶かし、水酸化ナトリウムでpH7.2〜7.5に調整した。さらに、安定化剤として亜硫酸ナトリウムを各々0、2.4、4.0mg/mLの濃度となるように添加した後、窒素で溶存酸素を除去し、濾過滅菌後、アンプルに窒素充填した。これらのアンプルを25℃4年間保存しグリチルリチンの沈殿の状況を観察し、また、これとは別に40℃4ケ月間及び60℃14日間保存した後、システインをHPLCで定量した。このようにして本発明医薬組成物の亜硫酸ナトリウム添加量の差による安定性を測定した結果の一例を表1に示す。
上記実施例1と同様に、グリチルリチン酸モノアンモニウム16mg/mL(グリチルリチンとして)、システイン塩酸塩8mg/mL、アミノ酢酸160mg/mLの配合比になるように溶存酸素の少ない水に溶かし、水酸化ナトリウムでpH7.2〜7.5に調整した。さらに、安定化剤として亜硫酸ナトリウムを6.4mg/mLとなるよう添加したものと無添加のものを作製し、また、これらの配合から、システイン塩酸塩の濃度が6mg/mL及び4mg/mLとなるように希釈したものも作製した。各々について、窒素で溶存酸素を除去し、濾過滅菌後、アンプルに窒素充填した。これらのアンプルを60℃14日間保存し、開始時、4日後、7日後、14日後にシステインをHPLCで定量した。このようにして本発明医薬組成物のシステイン塩酸塩の安定性に対する亜硫酸ナトリウム添加による影響を測定した結果の一例を表2に示す。
Claims (6)
- グリチルリチン2mgに対して、システインを0.77mg及びアミノ酢酸を20mgの割合で水に溶解した医薬組成物であって、グリチルリチン8乃至16mg/mL、システイン3乃至6mg/mL及びアミノ酢酸80乃至160mg/mLを含有し、亜硫酸塩を含有しない医薬組成物。
- グリチルリチンがグリチルリチン酸モノアンモニウムである請求項1記載の医薬組成物。
- システインがシステイン塩酸塩である請求項1又は2記載の医薬組成物。
- グリチルリチン酸モノアンモニウム8乃至16mg/mL(グリチルリチンとして)、システイン塩酸塩4乃至8mg/mL及びアミノ酢酸80乃至160mg/mLを含有する請求項1記載の医薬組成物。
- 肝臓疾患用薬剤である請求項1乃至4のいずれかに記載の医薬組成物。
- アレルギー用薬剤である請求項1乃至4のいずれかに記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003292135 | 2003-08-12 | ||
JP2003292135 | 2003-08-12 | ||
PCT/JP2004/011462 WO2005014009A1 (ja) | 2003-08-12 | 2004-08-10 | グリチルリチン高濃度製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005014009A1 JPWO2005014009A1 (ja) | 2006-09-28 |
JP4463206B2 true JP4463206B2 (ja) | 2010-05-19 |
Family
ID=34131698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005512629A Expired - Fee Related JP4463206B2 (ja) | 2003-08-12 | 2004-08-10 | グリチルリチン高濃度製剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060160754A1 (ja) |
EP (1) | EP1676580A4 (ja) |
JP (1) | JP4463206B2 (ja) |
KR (1) | KR101153250B1 (ja) |
CN (2) | CN1835758A (ja) |
AU (1) | AU2004263036B2 (ja) |
CA (1) | CA2534259C (ja) |
TW (1) | TWI316403B (ja) |
WO (1) | WO2005014009A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1818053A4 (en) * | 2004-11-02 | 2008-02-27 | Ajinomoto Kk | MEDICINE FOR THE TREATMENT / PROPHYLAXIS OF ALLERGIC DISEASES |
WO2008070121A1 (en) * | 2006-12-06 | 2008-06-12 | Cornell Research Foundation, Inc. | Intermediate duration neuromuscular blocking agents and antagonists thereof |
US8592451B2 (en) | 2009-03-17 | 2013-11-26 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
CN102573794B (zh) | 2009-08-19 | 2017-03-15 | 康奈尔大学 | 供生理注射用的半胱氨酸 |
CN102871958A (zh) * | 2012-09-24 | 2013-01-16 | 罗诚 | 一种含甘草酸单铵化合物药物组合物及其制备方法 |
ES2743075T3 (es) | 2013-04-29 | 2020-02-18 | Harsha Chigurupati | Toxicidad reducida en bebidas alcohólicas |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4150744A (en) * | 1976-02-27 | 1979-04-24 | Smith & Nephew Pharmaceuticals Ltd. | Packaging |
JPS5849310A (ja) * | 1981-09-17 | 1983-03-23 | Minofuaagen Seiyaku Honpo:Goushi | 有用なるグリチルリチン溶液の調製法 |
JPH0761946B2 (ja) * | 1986-07-26 | 1995-07-05 | 合資会社ミノフア−ゲン製薬本舗 | エイズ・ウイルス増殖抑制剤 |
US5030645A (en) * | 1990-10-15 | 1991-07-09 | Merck & Co., Inc. | Method of treating asthma using (S)-α-fluoromethyl-histidine and esters thereof |
JPH05271097A (ja) * | 1991-10-07 | 1993-10-19 | Asahi Chem Ind Co Ltd | アクレアシン類の可溶化剤および医薬組成物 |
JPH06135836A (ja) * | 1992-10-28 | 1994-05-17 | Minofuaagen Seiyaku Honpo:Goushi | コントラサプレッサー細胞の誘導剤 |
JP3415643B2 (ja) * | 1992-12-04 | 2003-06-09 | 株式会社ミノファーゲン製薬 | 筋ジストロフィー症治療薬 |
JP2002065808A (ja) * | 2000-08-30 | 2002-03-05 | Nisshin Seiyaku Kk | アミノ酸含有薬液入りプラスチック容器の安定な保存用包装体 |
JP3435405B2 (ja) * | 2000-11-24 | 2003-08-11 | 株式会社ティーセル研究所 | 家畜の乳房炎治療剤及びこれを用いた乳房炎の治療方法 |
JP2004522802A (ja) * | 2001-02-16 | 2004-07-29 | ラヴィファーム・ラボラトリーズ・インク | 水溶性で風味良い複合体 |
-
2004
- 2004-08-10 CN CNA200480022998XA patent/CN1835758A/zh active Pending
- 2004-08-10 AU AU2004263036A patent/AU2004263036B2/en not_active Ceased
- 2004-08-10 US US10/566,588 patent/US20060160754A1/en not_active Abandoned
- 2004-08-10 WO PCT/JP2004/011462 patent/WO2005014009A1/ja active Application Filing
- 2004-08-10 CN CN201010134563A patent/CN101773509A/zh active Pending
- 2004-08-10 EP EP04771449A patent/EP1676580A4/en not_active Withdrawn
- 2004-08-10 JP JP2005512629A patent/JP4463206B2/ja not_active Expired - Fee Related
- 2004-08-10 CA CA2534259A patent/CA2534259C/en not_active Expired - Fee Related
- 2004-08-10 KR KR1020067002767A patent/KR101153250B1/ko not_active IP Right Cessation
- 2004-08-11 TW TW093124048A patent/TWI316403B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2005014009A1 (ja) | 2005-02-17 |
CN1835758A (zh) | 2006-09-20 |
JPWO2005014009A1 (ja) | 2006-09-28 |
AU2004263036B2 (en) | 2010-06-03 |
TW200505469A (en) | 2005-02-16 |
EP1676580A1 (en) | 2006-07-05 |
AU2004263036A1 (en) | 2005-02-17 |
CA2534259C (en) | 2012-04-24 |
KR20060061351A (ko) | 2006-06-07 |
CN101773509A (zh) | 2010-07-14 |
KR101153250B1 (ko) | 2012-06-05 |
TWI316403B (en) | 2009-11-01 |
EP1676580A4 (en) | 2010-07-28 |
US20060160754A1 (en) | 2006-07-20 |
CA2534259A1 (en) | 2005-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2260429C9 (ru) | Составы моксифлоксацина, содержащие поваренную соль | |
JP5185488B2 (ja) | 2−(4−イソブチルフェニル)プロピオン酸の医薬組成物 | |
KR101202649B1 (ko) | 소듐 디클로페낙 및 β-시클로덱스트린을 포함하는 주사용약학 조성물 | |
EP2307056B1 (en) | Stabilized aqueous formulation containing paracetamol | |
EA035079B1 (ru) | Композиция диклофенака | |
JP6818019B2 (ja) | レファムリンの注射可能医薬組成物 | |
JP4463206B2 (ja) | グリチルリチン高濃度製剤 | |
JP5872551B2 (ja) | パラセタモールを含む医薬組成物およびその製造法 | |
US20040132823A1 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
CA3157999A1 (en) | Injectable compositions of ursodeoxycholic acid | |
WO2016170401A1 (en) | Novel injectable composition of diclofenac sodium | |
CA2496121A1 (en) | Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy | |
US7008934B2 (en) | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins | |
JP2001172183A (ja) | 眼科用医薬組成物 | |
US20130345160A1 (en) | Glycyrrhizin high-concentration preparation | |
JP2009155315A (ja) | 注射剤 | |
JP2004269363A (ja) | アセトアミノフェンを含有する安定な水性医薬組成物 | |
WO2020025986A1 (en) | Injectable combination of diclofenac sodium and thiocolchicoside | |
KR100738021B1 (ko) | 은행엽 엑스 고농도 함유 주사제 | |
OA17190A (en) | Injectable supersaturated acetaminophen solution for spinal administration. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090710 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100202 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100216 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130226 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140226 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |